The Motley Fool

Here’s why the Mesoblast limited share price is getting slammed today

Shares in regenerative medicine researcher Mesoblast limited (ASX: MSB) are down 11 per cent to $1.42 in trade today after media reports surfaced that Teva Pharmaceuticals had sold 29 million shares in the group at $1.50 each.

Shares in Tel Aviv-listed pharmaceutical giant Teva are down 60 per cent over the past year, but it’s no speculative biotech and has annual revenues of more than US$20 billion. It may just be a case of Teva looking to exit non-core positions then after a rough year.

Mesoblast does though fall into the speculative bucket given its lack of revenues and high cash burn as it continues to conduct multiple costly clinical trials designed to promote the efficacy of its regenerative medicine products to treat common human conditions such as back pain or rheumatoid arthritis.

If Mesoblast can successfully commercialise several of its products it may go onto reward early-stage investors.

However, given its cash flows debt is not an option and investors were asked to tip another $50 million into the business last August while it continues its clinical trials.

These 3 stocks could be the next big movers in 2020

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

In this FREE STOCK REPORT, Scott just revealed what he believes are the 3 ASX stocks for the post COVID world that investors should buy right now while they still can. These stocks are trading at dirt-cheap prices and Scott thinks these could really go gangbusters as we move into ‘the new normal’.

*Returns as of 6/8/2020

Motley Fool contributor Tom Richardson has no position in any stock mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Related Articles...

Latest posts by Motley Fool Staff (see all)